Blocking matrix-forming protein might prevent heart failure

April 13, 2018, Cincinnati Children's Hospital Medical Center
This microscopic image shows donated fibrotic heart cells from a patient who had heart failure. The cells have an elaborate fibronectin matrix (shown in red) which causes fibrosis and heart damage. In a study published by Circulation, researchers demonstrate a novel therapeutic peptide stops the process and heart fibrosis in mice with heart injury and human heart failure cells. Credit: Cincinnati Children's

Scientists used an experimental targeted molecular therapy to block a matrix-forming protein in heart cells damaged by heart attack, reducing levels of scarred muscle tissue and saving mouse models from heart failure.

Researchers at the Cincinnati Children's Heart Institute report in the journal Circulation testing a manufactured peptide called pUR4 to block the fibronectin protein in human donated by patients. The treatment prevented the human from failing and restored their function. The treatment also reduced fibrosis and improved heart function after a simulated heart attack in mice.

Fibronectin is normally a good actor in the body. It helps form a cell-supporting matrix for the body's connective tissues, aiding tissue repair after injury.

But after a heart attack, fibronectin overreacts, it polymerizes and helps produce too much connective matrix. It also causes hyperactive production of clogged and dysfunctional cardio myofibroblast cells that damage the heart. The pUR4 compound is designed so it will attach to surface points on fibronectin, effectively inhibiting its effects in injured heart cells.

"Our data are a strong proof of principle and the first to show that inhibiting fibronectin polymerization preserves heart function, reduces left ventricle remodeling and limits formation of fibrotic connective tissue," said the study's lead investigator Burns Blaxall, PhD, director of translational research in the Heart Institute and the Center for Translational Fibrosis Research.

In this image, human heart cells treated with a novel therapeutic peptide exhibit dramatically reduced fibrosis. The experimental treatment prevented the human heart cells from failing and restored their function. Credit: Cincinnati Children's
Testing a Tiny Solution for a Big Problem

Although heart disease is the leading cause of death in the world, few effective treatment options are available for patients—many having had a previous heart attack or . The pUR4 molecular treatment used in the current study is one of several compounds Blaxall and his colleagues are testing that show promise in preliminary preclinical research data.

Heart fibrosis and cardiac remodeling are medical challenges that are also faced by children with congenital heart disorders, and ongoing medical challenges requiring specialized care often follow these children into adulthood.

A key question in the current Circulation study was verifying the results of pUR4 targeted molecular therapy in both the mouse models and human heart failure cells. In mice with simulated heart attack that as a control experiment received a placebo therapy, the animals developed significant fibrosis and heart failure. When researchers treated mice with pUR4 for just the first seven days after , or genetically deleted fibronectin activity from the heart cells of mice, these reduced fibrosis and improved cardiac function. Treatment of human failing heart cells with pUR4 also reduced their fibrotic behavior.

Next Steps

The researchers emphasize it's too early to know whether the experimental therapy in this study can one day be used to treat human heart patients clinically. Extensive additional research is needed first, including proving pUR4's safety in larger animal models and then moving on to establish proof-of-principal effectiveness treating heart failure in those models, according to Blaxall.

Researchers also are working to refine the pUR4 peptide to enhance its capabilities for localized administration to the heart and for extended-release in patients.

Explore further: Vitamin D may help prevent heart failure after heart attack

More information: Iñigo Valiente-Alandi et al, Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure, Circulation (2018). DOI: 10.1161/CIRCULATIONAHA.118.034609

Related Stories

Vitamin D may help prevent heart failure after heart attack

March 8, 2018
New research has shown how vitamin D may help protect heart tissue and prevent heart failure after a heart attack, potentially offering a low-cost addition to existing treatments for heart failure.

Study hints at experimental therapy for heart fibrosis

August 14, 2017
Researchers report encouraging preclinical results as they pursue elusive therapeutic strategies to repair scarred and poorly functioning heart tissues after cardiac injury—describing an experimental molecular treatment ...

How Gata4 helps mend a broken heart

August 15, 2017
During a heart attack, blood stops flowing into the heart; starved for oxygen, part of the heart muscle dies. The heart muscle does not regenerate; instead it replaces dead tissue with scars made of cells called fibroblasts ...

Scientists test way to stop heart damage after cardiac injury

September 28, 2017
Early research results suggest scientists might be on to a way to preserve heart function after heart attacks or for people with inherited heart defects called congenital cardiomyopathies.

Scientists reverse advanced heart failure in an animal model

October 4, 2017
Researchers have discovered a previously unrecognized healing capacity of the heart. In a mouse model, they were able to reverse severe heart failure by silencing the activity of Hippo, a signaling pathway that can prevent ...

Protein could be new target to reduce damage after heart attack

February 24, 2011
Scientists have identified a protein that plays a key role in debilitating changes that occur in the heart after a heart attack, according to research reported in Circulation Research: Journal of the American Heart Association.

Recommended for you

Higher risk of heart attack on Christmas Eve

December 12, 2018
The risk of heart attack peaks at around 10pm on Christmas Eve, particularly for older and sicker people, most likely due to heightened emotional stress, finds a Swedish study in this week's Christmas issue of The BMJ.

Your weight history may predict your heart failure risk

December 12, 2018
In a medical records analysis of information gathered on more than 6,000 people, Johns Hopkins Medicine researchers conclude that simply asking older adult patients about their weight history at ages 20 and 40 could provide ...

Age is the biggest risk for heart disease, but lifestyle and meds have impact

December 12, 2018
Of all the risk factors for heart disease, age is the strongest predictor of potential trouble.

New understanding of mysterious 'hereditary swelling'

December 12, 2018
For the first time ever, biomedical researchers from Aarhus University, Denmark, report cellular defects that lead to a rare disease, hereditary angioedema (HAE), in which patients experience recurrent episodes of swelling ...

Research team traces pathway to cardioprotection in post-ischemic heart failure

December 11, 2018
During an ischemic attack, the heart is temporarily robbed of its blood supply. The aftermath is devastating: reduced heart contractility, heart cell death, and heart failure. Contributing to these detrimental changes is ...

Macrophage cells key to helping heart repair—and potentially regenerate, new study finds

December 11, 2018
Scientists at the Peter Munk Cardiac Centre have identified the type of cell key to helping the heart repair and potentially regenerate following a heart attack.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.